SkyPASS: A Prospective, Non-interventional (NIS), Long-term, Post-Authorization Safety Study (PASS) of Patients Treated with SKYTROFA (Lonapegsomatropin)
Multi-center, prospective, non-interventional, post-marketing observational study of patients prescribed SKYTROFA to treat Growth Hormone Deficiency (GHD) in the United States and Europe.
Ages: 1 to 18 years old on treatment of SKYTROFA (Lonapegsomatropin)
Patients are managed according to routine clinical practice. Assessments are standard of care.
Every 3 months new data will be collected, if available.
Patients are followed for at least 5 years after eligibility
Interested?
Either call Dr. Miller's Research Team at 612-624-5409 or email at [email protected]
Also, the study is registered on the ClinicalTrials.gov Website at: https://clinicaltrials.gov/study/NCT05775523intr=SKYTROFA&aggFilters=ages:child&rank=2